Regenerative implant producer OssDsign, based on research at Karolinska University Hospital and Uppsala University, hopes to list on the Nasdaq First North and raise $15.8m.
OssDsign, a Sweden-based regenerative implant producer backed by Karolinska Development, the investment arm of Karolinska Institute, is aiming to list on the Nasdaq First North following a Skr151.3m ($15.8m) initial public offering.
The company will issue 5.5 million shares priced at about $2.90 each, implying a pre-money valuation for OssDsign of $35.1m.
Approximately 74% of the shares, worth some $11.7m in total, have already been subscribed to by institutional and private investors including Alto Invest, Handelsbanken Fonder, Lancelot…
